Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics reported a net loss attributable to Lineage of $63.5 million for FY 2025, a significant increase from an $18.6 million loss in FY 2024. Total revenues grew 53% year-over-year to $14.6 million, primarily driven by a $5.5 million increase in collaboration revenues, including a $5.0 million milestone payment from Roche and $2.5 million from a new research collaboration with WDI. However, operating expenses surged 65% to $51.2 million, largely due to a $14.8 million non-cash impairment charge for the abandoned VAC platform and increased R&D spending. The company ended the year with $55.8 million in cash, cash equivalents, and marketable securities, which it believes is sufficient to fund operations for at least the next twelve months.

Key Takeaways